FDA Panel Backs 2 Hepatitis C Drugs
A major advance for treating hepatitis C is likely headed to market after government advisors backed two new drugs: telaprevir and boceprivir.
Click here to read the full story.
No profanity or inappropriate comments will be allowed.
Offensive posters will be blocked from future postings.
The content has been reported and it will be reviewed by a moderator.
